Elevated Neutrophil–to–Lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with trastuzumab combination chemotherapy

Gi Yong Hwang, Dong Won Baek, Hee Jeong Cho, Soo Jung Lee, Yee Soo Chae, Byung Woog Kang, In Hee Lee, Jong Gwang Kim, An Na Seo, Han Ik Bae, Ki Bum Park, Ji Yeon Park, Oh Kyoung Kwon, Seung Soo Lee, Ho Young Chung

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background/Aim: This study investigated the clinical prognostic relevance of the neutrophil-to-lymphocyte ratio (NLR) in patients with human epidermal receptor 2 (HER2)-positive metastatic advanced gastric cancer (AGC) treated with combination chemotherapy including trastuzumab. Patients and Methods: This is a retrospective analysis of 73 patients diagnosed with metastatic AGC who were treated with trastuzumab combination chemotherapy. NLR was calculated as the neutrophil count divided by the lymphocyte count. A cutoff value of 3 was selected, which classified patients into two categories, low (≤3.0) or high (>3.0). Results: In the univariate analysis, the high-NLR patients showed a significantly shorter progression-free survival (PFS) and overall survival (OS) than the low-NLR patients (PFS, p=0.012, OS, p=0.047). In the multivariate analysis, the high NLR was independently associated with a shorter PFS (p=0.015) and OS (p=0.040). Conclusion: This study found that a high NLR was associated with a shorter PFS and OS in patients with HER2-positive gastric cancer treated with trastuzumab.

Original languageEnglish
Pages (from-to)3151-3156
Number of pages6
JournalAnticancer Research
Volume38
Issue number5
DOIs
StatePublished - May 2018

Keywords

  • Gastric cancer
  • Neutrophil-to-lymphocyte ratio
  • Prognostic factor
  • Trastuzumab

Fingerprint

Dive into the research topics of 'Elevated Neutrophil–to–Lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with trastuzumab combination chemotherapy'. Together they form a unique fingerprint.

Cite this